Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a pinnacle of $51.88. With a market capitalization of $4.12 billion and an ...

Verona Pharma operates in a competitive COPD market, but Ohtuvayre’s differentiated mechanism of action and competitive pricing strategy position it well against established players. The product ...

and now Verona has revealed the drug made approximately $36 million in the final three months of 2024, off more than 16,000 prescriptions. Chief executive David Zaccardelli said Ohtuvayre was off ...

Ohtuvayre is due to launch in the US in the third quarter of this year, assisted by a $650 million debt facility that Verona agreed a few months ago to build its commercial capabilities.

Verona Pharma stock hit a record high Thursday — running up 19% over the past four days — on continued enthusiasm for its COPD treatment, Ohtuvayre. Please watch the video at Investors.com ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...

In Nov 2024, Nuance Pharma launched Ohtuvayre™ in China's Hainan Boao Pilot Zone through early access program. In Sep 2024, Nuance Pharma completed recruitment for ENHANCE- CHINA, the phase 3 clinical ...